Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by Mt69sinaion Jan 21, 2020 7:17am
355 Views
Post# 30576705

Aphria Inc. Receives EU GMP Certification for Subsidiary

Aphria Inc. Receives EU GMP Certification for Subsidiary
Aphria Inc. Receives EU GMP Certification for Subsidiary ARA-Avanti Rx Analytics 

COMTEX - Updated 21 minutes ago 
CNW Group

Certification allows the Company to begin to supply medical cannabis across the European Union

First shipment expected to occur in fourth quarter

Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that it has received its European Union Good Manufacturing Practices ("EU GMP") certification in respect of medicinal products for human use and investigational medicinal products for human use, from the Malta Medicines Authority ("MMA") at the Company's subsidiary, ARA - Avanti Rx Analytics.

Aphria selected the MMA to perform the EU GMP audit as the criteria and certification thresholds established by the MMA are among the most stringent and demanding in the EU. The certification will allow the Company to ship bulk and finished dried flower, as well as bulk and finished cannabis oil for medicinal use in permitted jurisdictions throughout the European Union.

"We believe that this is a game changer for Aphria Inc. and will significantly advance our leadership in permissible medical cannabis markets across Europe, where demand for product is strong," said Irwin D. Simon, Chief Executive Officer. "With 2.4 million square feet of licensed production capacity of up to 255,000 kilograms, state-of-the-art greenhouses and labs, and our global infrastructure, we believe Aphria is well positioned to lead in the Canadian and international markets."

Aphria's German operations have been preparing for the importation of EU-GMP certified cannabis from Canada, allowing for shipments to the Company's German subsidiary CC Pharma GmbH ("CC Pharma") in order to leverage CC Pharma's expansive in-country distribution network. The Company anticipates that its first shipments of medical cannabis to CC Pharma will occur in its fourth quarter of its fiscal 2020.

$$$$$APHA$$$$$


Bullboard Posts